Obesity Clinical Trial
To evaluate additional cardiovascular risk factors using data from the VA HDL Intervention Trial (VA-HIT).
BACKGROUND:
The VA HDL Intervention trial (VA-HIT) was a multicenter, placebo controlled, randomized
trial that showed that gemfibrozil significantly reduced major cardiovascular events in 2531
men with coronary heart disease, low levels of low density lipoprotein (LDL) cholesterol and
low levels of high density lipoprotein (HDL) cholesterol. In addition to its unique lipid
profile, the VA-HIT population also had a high prevalence of diabetes, impaired fasting
glucose, or high fasting plasma insulin; central obesity; and hypertension, which are all
components (together with high triglycerides and low HDL-cholesterol) of a constellation of
risk factors known as the metabolic syndrome. Since prior clinical trials have not enrolled
this type of population, the VA- HIT database is a unique resource.
DESIGN NARRATIVE:
The study used the VA-HIT database to study additional risk markers that were measured in
the study population of 2,531 men with coronary heart disease. Specific analyses were: 1)
the association between levels of glucose tolerance, insulin resistance and other features
of the metabolic syndrome, occurrence of major cardiovascular outcomes, and gemfibrozil
efficacy; 2) the effect of gemfibrozil on progression of carotid atherosclerosis, as
measured by B-mode ultrasound; 3) the association between LDL particle size distribution and
lipoprotein subclass distribution; homocysteine; lipoprotein(a); C-reactive protein, tissue
plasminogen activator; fibrinogen; and factor VII; major cardiovascular outcomes and
gemfibrozil efficacy.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |